Severe hydroxychloroquine non-adherence linked to worse SLE outcomes

From Rheumatology News, 25 May 2023: Regular testing of hydroxychloroquine levels in patients with systemic lupus erythematosus – especially those who are experiencing a disease flare – could help to identify patients who are not taking their treatment and are at risk of worse outcomes. Data presented at an international congress on systemic lupus erythematosus Continue reading Severe hydroxychloroquine non-adherence linked to worse SLE outcomes

Patient selection key to lowering placebo response rates in lupus clinical trials

From Rheumatology News, 13 June 2023: A major challenge for clinical trials in systemic lupus erythematosus (SLE) is how to get the placebo response rate down low enough that the effectiveness of a drug can actually be seen. Better patient selection may be the key. Speaking at an international congress on SLE, Joan Merrill, MD, Continue reading Patient selection key to lowering placebo response rates in lupus clinical trials